Kintara Therapeutics (STU:3DMA) 3-Year EBITDA Growth Rate : 38.40% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics 3-Year EBITDA Growth Rate?

Kintara Therapeutics's EBITDA per Share for the three months ended in Dec. 2023 was €-0.21.

During the past 3 years, the average EBITDA Per Share Growth Rate was 38.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 47.70% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 15.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Kintara Therapeutics was 51.70% per year. The lowest was -616.70% per year. And the median was 15.45% per year.

Competitive Comparison of Kintara Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Kintara Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kintara Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's 3-Year EBITDA Growth Rate falls into.

Kintara Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Kintara Therapeutics (STU:3DMA) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Kintara Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintara Therapeutics (STU:3DMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (STU:3DMA) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

KTRA:USA

Address

9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121

Website

https://www.kintara.com

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics (STU:3DMA) Headlines

No Headlines